Provided by Tiger Trade Technology Pte. Ltd.

Jasper Therapeutics

1.35
+0.08006.30%
Post-market: 1.370.0200+1.48%18:58 EST
Volume:526.34K
Turnover:720.90K
Market Cap:37.78M
PE:-0.23
High:1.41
Open:1.30
Low:1.28
Close:1.27
52wk High:7.19
52wk Low:1.26
Shares:27.98M
Float Shares:22.81M
Volume Ratio:1.15
T/O Rate:2.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.7868
EPS(LYR):-4.8865
ROE:-191.12%
ROA:-72.92%
PB:3.26
PE(LYR):-0.28

Loading ...

Jasper Therapeutics initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
Jan 14

Jasper Therapeutics Showcases Briquilimab’s Potential in Targeted Mast Cell Depletion for Inflammatory Diseases

Reuters
·
Jan 13

Briquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating

TIPRANKS
·
Jan 09

Jasper Therapeutics Reports Positive Updated Data From Briquilimab Studies in Chronic Spontaneous Urticaria

THOMSON REUTERS
·
Jan 08

Jasper Therapeutics Reports Positive Briquilimab Data in Chronic Spontaneous Urticaria Study

Reuters
·
Jan 08

BRIEF-Jasper Therapeutics Appoints Jeet Mahal As Chief Executive Officer To Lead Next Phase Of Clinical Growth

Reuters
·
Jan 08

Jasper Therapeutics Names Jeet Mahal CEO and Thomas Wiggans Executive Chairperson

Reuters
·
Jan 08

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

THOMSON REUTERS
·
Jan 08

Jasper Therapeutics Inc - Thomas Wiggans Appointed as Executive Chairperson of Jasper

THOMSON REUTERS
·
Jan 08

BUZZ-Jasper Therapeutics jumps as asthma drug shows early promise

Reuters
·
Dec 02, 2025

Jasper Therapeutics Inc: Briquilimab Was Well Tolerated in Study, Demonstrating a Favorable Safety Profile

THOMSON REUTERS
·
Dec 02, 2025

Jasper Therapeutics Reports Positive Preliminary Data From Etesian Study of Briquilimab in Asthma and Findings From Beacon Study Internal Investigation

THOMSON REUTERS
·
Dec 02, 2025

Jasper Therapeutics Inc: Completion of Internal Beacon Study Investigation Noting No Deviations or Issues With Drug Product Utilized

THOMSON REUTERS
·
Dec 02, 2025

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM

Reuters
·
Dec 02, 2025

Jasper Therapeutics to Present Preliminary Asthma and Urticaria Study Data in Investor Webinar

Reuters
·
Dec 02, 2025

Jasper Therapeutics Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Nov 11, 2025

Jasper Therapeutics Showcases Briquilimab’s Strong Efficacy and Safety in Chronic Urticaria

Reuters
·
Nov 11, 2025

CoreWeave Bulls Should Brace For 'Wild, Lumpy, Volatile Ride,' JPMorgan Says

Benzinga_recent_news
·
Nov 11, 2025

RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Nov 11, 2025

Jasper Therapeutics (JSPR) Receives a Hold from William Blair

TIPRANKS
·
Nov 11, 2025